Joseph Haas is a Senior Writer at Informa. He specializes in medicine and healthcare, with a focus on medical technology, alternative medicine, and various medical specialties, as well as business and economics within the healthcare sector. His work has been featured in notable publications including Informa, Citeline, and MDEdge.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Joseph Haas focuses on the healthcare and pharmaceutical industry, particularly mergers and acquisitions, drug development, and clinical trials. His coverage heavily features press releases from pharmaceutical companies and private sector announcements.
Given this focus, Joseph would likely be interested in pitches related to new M&A deals in the biopharmaceutical industry or significant advancements in drug development. Sources with insights into the strategic aspects of these transactions or specific clinical trial results may capture his attention.
When reaching out to Joseph, it's important to have access to reliable data that supports any claims being made as he frequently cites data in his articles. Additionally, understanding the intricacies of the biopharmaceutical industry will be crucial when crafting a pitch for him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Joseph Haas, Dexter Jie Yan, Lisa Takagi
Plus deals involving Fulcrum/Slate, Oblenio/Leads Biolabs, GSK/Chugai, IASO/MediSix, Innate/SOBI and more.
Bausch + Lomb said its eye drop combining the active ingredients from Xiidra and Miebo will soon move into Phase III. The firm is also bullish on a Phase II ocular surface pain candidate.
By: Joseph Haas
Deal snapshot: South Korea's SK Biopharmaceuticals will add opakalim to its epilepsy portfolio, paying Biohaven $350m at closing for the Phase II/III ion channel modulator.
By: Joseph Haas
Roivant's Priovant subsidiary gained US approval of brepocitinib in dermatomyositis. Priovant is pursuing additional indications for what is expected to be a blockbuster seller.
With approval to treat essential thrombocytopenia, Besremi, already indicated to treat polycythemia vera, will face off against entrenched generics with an emphasis on addressing underlying disease pathology.
Recent FDA nod for mFLUSIVA may have opened the door for other novel flu vaccine approaches. GSK is moving into Phase III, while Osivax and GC announced a T-cell program, one of an estimated 46 next-gen flu vaccine candidates advancing in the clinic.
By: Joseph Haas
Targeting patients with the TP53 Y220C mutation, thought to be present in about 3.2% of ovarian cancer cases, PMV says rezatapopt could offer overall response and durable response benefits over chemotherapy.
By: Joseph Haas
TEV'408 brings in positive Phase IIa data in patients with celiac disease, which has no approved drug therapy. Teva sees the antibody offering potential in multiple GI and dermatology indications.
By: Vibha Ravi, Joseph Haas, Lisa Takagi
Plus deals involving Novartis/Alteogen, Evotec/Plectonic, Leios/CMS, Heidelberg/Huadong, Lupin/Visus and more.
By: Joseph Haas
Built around five BMS pipeline assets and financed by Bain Capital, Beeline has TLR7/8 inhibitor afimetoran successfully through Phase II in SLE and hopes to begin pivotal studies in SLE and the cutaneous form of lupus.
